The continued prevalence of MS and the current and ongoing advances in the diagnosis and management of the disease inevitably create knowledge and performance gaps for neurologists and other health care providers who care for patients with MS. This curriculum is designed to provide high-quality, up-to-date information on advances in the treatment of MS.
The continued prevalence of MS and the current and ongoing advances in the diagnosis and management of the disease inevitably create knowledge and performance gaps for neurologists and other health care providers who care for patients with MS. To address the identified educational needs of these providers, the Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and The France Foundation have created the AIMS (Advances In Multiple Sclerosis) Curriculum. This curriculum is designed to provide high-quality, up-to-date information on advances in the treatment of MS.
Bring your own patient case questions.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and The France Foundation. The CMSC is accredited by the ACCME to provide continuing medical education for physicians.
CMSC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Alternatives is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 3.0 contact hour(s) of continuing nursing education for RNs and APRNs.
Laurie Scudder DNP, NP, has served as Nurse Planner for this activity. She has declared that she has no relevant financial relationships to disclose.
Accreditation of this program does not imply endorsement by NPA, CMSC, or ANCC.
Sponsored through an educational collaboration by the CMSC, NPA, and The France Foundation.
Supported by educational grants from EMD Serono, Novartis, and Teva.
The Consortium of Multiple Sclerosis Centers, The France Foundation, and Nurse Practitioner Alternatives adhere to ANCC and ACCME Essential Areas, Standards, and Policies regarding industry support of continuing medical education. Disclosure of the planning committee, content reviewers, and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.
In accordance with the ANCC and ACCME Standards for Commercial Support of CME, the Consortium of Multiple Sclerosis Centers, The France Foundation, and Nurse Practitioner Alternatives will implement mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.
There is no fee for this activity, however you will be asked to provide credit card information to guarantee your reservation. Credit cards will be charged a one-time $25 fee ONLY if you do not attend or do not cancel your registration by three days before the event. Registration is granted on a first-come, first-served basis as space is limited. We encourage you to register early and reserve your space, as we cannot guarantee that we can accommodate onsite registration.
Please click on this link to register: www.cmeAIMS.org
Please contact firstname.lastname@example.org.
Forgot your password?
Haven't registered yet?
12/5/2016CMSC INforMS: Low Vitamin D Levels at Birth May Influence MS Risk in Adults, Study Suggests
12/1/2016CMSC INforMS: ICER Releases Draft Report on Disease-modifying Therapies for MS, Welcomes Comment
11/29/2016CMSC INforMS: UV Light May Lead Way to New Treatment for MS and Inflammation
11/21/2016CMSC INforMS: Acorda to Discontinue Dalfampridine for Treatment of Post-Stroke Walking Difficulties
11/14/2016CMSC INforMS: Genentech Results from Survey that shows Everyday Impact of Unpredictable MS Symptoms
5/24/2017 » 5/27/20172017 CMSC Annual Meeting
6/24/2017 » 6/27/20173rd Congress of the European Academy of Neurology (EAN)
5/30/2018 » 6/2/20182018 CMSC Annual Meeting
5/29/2019 » 6/1/20192019 CMSC Annual Meeting